Nusano News
Nusano Announces September 2025 Conference Schedule
WEST VALLEY CITY, Utah – Sept. 4, 2025 – Nusano, a leader in advanced isotope and energy technologies, today announced its September conference schedule. Nusano CEO...
Nusano to Participate in the 2nd Annual Guggenheim Securities Radiopharmaceuticals Day
Nusano, Inc., a company reshaping the production of cancer-fighting radioisotopes, today announced it will participate in a fireside chat at the 2nd Annual Guggenheim Securities Radiopharmaceuticals Day in New York City on Monday, May 15, 2023.
Nusano to Host Key Opinion Leader Webinar on Isotope Production and Applications for Oncology Radio-pharmaceuticals
Nusano is hosting a virtual Key Opinion Leader (KOL) event on Friday, May 12, 2023 at 10 a.m. EST. The event will highlight the rapidly expanding and critically undersupplied medical radioisotopes market, including current limitations and what must be overcome to improve patient care and unlock market potential.
Nusano to Present Production Capabilities to European Radiopharmaceuticals Working Group
Nusano will present an overview of the company’s breakthrough production platform to the European Cooperation in Science and Technology (COST) Astatine-211 Working Group on May 4, 2023. Presentation materials will be available on the company’s website following the event.
Nusano Co-Founder Dr. Howard Lewin to Participate in Truist Securities Virtual Radiopharmaceuticals Event
Nusano’s Dr. Howard Lewin will take part in a virtual event hosted by Truist Securities on Friday, April 21, 2023, at 3:30 p.m. Eastern.
Nusano Announces Q1 2025 Opening Date for Medical Radioisotope Production Facility in Utah
Nusano’s breakthrough production facility will open Q1 2025 in West Valley City, Utah.
Nusano to Present at Jefferies Inaugural Radiopharma Innovation Summit
Nusano is a featured panelist and speaker at Jefferies Inaugural Radipharma Innovation Summit in New York City on April 3, 2023
Chris Lowe Named CEO
VALENCIA, Calif. and WEST VALLEY CITY, Utah, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Nusano, Inc., a company reshaping the production of cancer-fighting radioisotopes, today announced Chris Lowe as the company’s Chief Executive Officer. As Nusano progresses toward...
Nusano Raises $41M in Seed Round
Nusano (previously known as Alpha Source Inc./Alpha Isotopes) filed paperwork with the United States Securities and Exchange Commission on October 24, 2018 detailing a $41 million seed funding round from investors. With its patented technology, Nusano is working...
Health-Tech Company Nusano To Open an Office in Utah
SALT LAKE CITY – July 8, 2021 – The Utah Governor’s Office of Economic Opportunity is pleased to announce that Nusano, Inc. will open an office in Utah, adding up to 92 new high-paying Utah jobs in the next 15 years. “Nusano will be an awesome addition to...
BLOG Posts
ICR: ‘Search and destroy’ treatment improves quality of life for patients with advanced prostate cancer
News from the United Kingdom's Institute of Cancer Research (ICR) published in The Lancet Oncology reports that...
Case Study: Radioisotope supply challenges affecting prostate cancer treatment
Experts at the Dana-Farber Cancer Institute report patient treatments were delayed by three months due to low supply of 177Lu-PSMA-617.
Welsh Government seeks to create ‘global centre of excellence in nuclear medicine’
The Welsh Government is working to secure a stable supply of medical radioisotopes for United Kingdom citizens for decades to come.
DISCOVER MORE ABOUT NUSANO
Sign up to receive company news and updates